Medicine to Solid Organs
We unleash the power of novel therapeutics by delivering them directly to the targeted organ.
Specializing in direct to organ delivery solutions for advanced medicine.
Schlieren/Zurich, Switzerland
US Office:
Laguna Hills, CA, USA
8952 Schlieren/Zurich
P: +41 55 417 40 50
Advancing combinatory products into the clinic
Experimental and programmatic design
System design, prototype and modifications to target organs to fit therapeutic purpose
Conducting use experiments and refinements to achieve TPP
Build and scale delivery system that is ready for multi-organ and clinical use
Targeting disease areas with high unmet medical needs and attractive commercial opportunities, where direct to organ delivery system can unleash full potential of therapeutics
Development of solution per targeted organ for the DiNATEQ™ system partnering with drug development companies
Highly talented, cross-functional team combining expertise across anatomy, therapeutics and medical device
Broad range of alliances and partnership from single-asset to therapeutic fields across multiple modalities
Combining the potential of licensing and development fees, milestones and royalties
Effectiveness of the system is supported through ongoing R&D with payloads and by comprehensive clinical data
Johannes Holzmeister is an internationally recognized cardiologist and is the Co-Founder, Chairman and Chief Executive Officer at DiNAQOR.
Dr. Holzmeister has more than two decades of clinical research experience . He was an attending physician at Charité, one of Europe’s largest teaching hospitals and one of Germany’s top medical research institutions. He also worked at the University Hospital of Zürich, where he led the interventional device group for heart failure patients.
In 2010, Dr. Holzmeister founded and served as CEO of Cardiorentis, a biopharmaceutical company offering a technology platform integrating expertise in protein biology to identify novel targets and design small molecule compounds and peptides for healthcare markets, including in the areas of heart failure and other cardiovascular diseases.
Dr. Holzmeister’s research has been published in leading medical journals including The New England Journal of Medicine and The Lancet. He received his MD from Humboldt University of Berlin.
Mark Dehdashtian is a product development leader with decades of experience developing disruptive technologies and bringing new therapies to market to help patients address unmet medical needs.
Mr. Dehdashtian spent 25 years in leadership roles at Edwards Lifesciences, including serving as the company’s Vice President of Research and Development for its Heart Valve Therapy, Advanced Technology and Cardiac Surgery Systems divisions. At Edwards, Mr. Dehdashtian designed the delivery systems for transcatheter heart valves and was instrumental in commercializing the transcatheter heart valve transapical systems.
He holds more than 60 U.S. patents as well as many international patents, most notably for the design of the transcatheter heart valve, and his work has been published in several peer-reviewed journals. Mr. Dehdashtian has also served as a member of medical technology steering committees to develop industry-wide standards.
He obtained a MS in Technology Management from Pepperdine Graziadio Business School.
Chris Rusconi is a biotechnology entrepreneur, inventor, and innovator with a focus on the oligonucleotide space and extensive drug discovery and development experience.
An expert in leveraging platform science to create product pipelines, Dr. Rusconi has held leadership roles with both publicly traded and privately held companies. He spearheaded the science of Regado Biosciences from its founding through multiple rounds of private equity raises, IPO and secondary public offerings to a market capitalization of more than $400 million. He is an inventor on more than 70 issued and pending patents and author of more than 40 peer-reviewed publications.
Before joining DiNATEQ Dr. Rusconi worked at PKD Foundation, a not-for-profit organization dedicated to finding treatments and a cure for polycystic kidney disease (PKD). He also served as the Chief Scientific Officer at Vitrisa Therapeutics, the founding CEO of Ribometrix, and was a co-founder and Chief Scientific Officer at Regado Biosciences. Prior to Regado he served as director of research for the Program in Combinatorial Therapeutics and as an assistant research professor of surgery at Duke University Medical Center.
He earned a PhD in Molecular and Cellular Biology from the University of Colorado, Boulder as an NSF Graduate Fellow and was a Jane Coffin Childs Postdoctoral Fellow at Duke University.
Steven Zelenkofske has more than 20 years of biopharmaceutical, medical device and gene therapy industry expertise and more than a decade of cardiovascular academic and clinical experience.
An expert in clinical development and adaptive trial design and operations, Dr. Zelenkofske has been responsible for multiple NDA filings and approvals throughout his career. He has held leadership positions at SwanBio Therapeutics, Achillion Pharmaceuticals, uniQure, Regado Biosciences, AstraZeneca, Sanofi-Aventis, and Boston Scientific. His work has spanned numerous therapeutic areas including neurology, immunology, hematology, cardiovascular, metabolic diseases, diabetes, and nephrology.
He holds BS and MS degrees from Emory University and a D.O. from the Philadelphia College of Osteopathic Medicine. He conducted his graduate medical education at the Philadelphia College of Osteopathic Medicine and is board-certified in internal medicine, cardiology, and cardiac electrophysiology.
Bio Coming Soon